Benjamin F. Edwards & Company, Inc. Biogen Inc. Transaction History

Benjamin F. Edwards & Company, Inc.

$5.69 Billion
Q2 2024

A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 859 shares of BIIB stock, worth $135,258. This represents 0.0% of its overall portfolio holdings.

Number of Shares

859

Previous 909 5.5%

Holding current value

$135,258

Previous $196,000 1.53%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$190.52 - $236.72 $9,526 - $11,836	-50 Reduced 5.5%	859 $199,000
Q1 2024 Apr 29, 2024	SELL	$212.02 - $267.71 $4,664 - $5,889	-22 Reduced 2.36%	909 $196,000
Q1 2023 Apr 27, 2023	SELL	$256.56 - $292.34 $4,104 - $4,677	-16 Reduced 1.69%	931 $259,000
Q4 2022 Feb 07, 2023	SELL	$252.44 - $306.72 $6,311 - $7,668	-25 Reduced 2.57%	947 $262,000
Q3 2022 Oct 28, 2022	SELL	$194.69 - $268.46 $20,053 - $27,651	-103 Reduced 9.58%	972 $260,000
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $30,193 - $35,906	-161 Reduced 13.03%	1,075 $219,000
Q1 2022 May 04, 2022	SELL	$193.77 - $244.14 $21,896 - $27,587	-113 Reduced 8.38%	1,236 $260,000
Q4 2021 Feb 07, 2022	SELL	$223.92 - $287.77 $255,940 - $328,921	-1,143 Reduced 45.87%	1,349 $324,000
Q3 2021 Nov 02, 2021	BUY	$282.99 - $369.05 $38,203 - $49,821	135 Added 5.73%	2,492 $705,000
Q2 2021 Aug 11, 2021	SELL	$259.0 - $414.71 $79,513 - $127,315	-307 Reduced 11.52%	2,357 $816,000
Q1 2021 May 14, 2021	SELL	$242.95 - $284.63 $14,091 - $16,508	-58 Reduced 2.13%	2,664 $745,000
Q4 2020 Feb 16, 2021	SELL	$236.26 - $355.63 $16,065 - $24,182	-68 Reduced 2.44%	2,722 $667,000
Q3 2020 Nov 13, 2020	SELL	$264.77 - $305.71 $3,706 - $4,279	-14 Reduced 0.5%	2,790 $791,000
Q2 2020 Aug 14, 2020	SELL	$258.66 - $342.55 $17,588 - $23,293	-68 Reduced 2.37%	2,804 $750,000
Q1 2020 May 07, 2020	SELL	$268.85 - $341.04 $66,137 - $83,895	-246 Reduced 7.89%	2,872 $909,000
Q4 2019 Feb 06, 2020	BUY	$220.06 - $304.07 $8,802 - $12,162	40 Added 1.3%	3,118 $925,000
Q3 2019 Nov 05, 2019	BUY	$217.44 - $243.88 $466,191 - $522,878	2,144 Added 229.55%	3,078 $717,000
Q2 2019 Aug 08, 2019	BUY	$219.29 - $241.72 $63,374 - $69,857	289 Added 44.81%	934 $218,000
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $5,201 - $8,135	24 Added 3.86%	645 $152,000
Q4 2018 Jan 31, 2019	SELL	$278.5 - $352.75 $5,570 - $7,055	-20 Reduced 3.12%	621 $187,000
Q3 2018 Oct 29, 2018	SELL	$293.51 - $383.83 $4,402 - $5,757	-15 Reduced 2.29%	641 $226,000
Q2 2018 Jul 19, 2018	BUY	$257.52 - $306.91 $77,513 - $92,379	301 Added 84.79%	656 $190,000
Q1 2018 Apr 17, 2018	SELL	$260.13 - $367.91 $50,205 - $71,006	-193 Reduced 35.22%	355 $97,000
Q4 2017 Jan 17, 2018	SELL	$307.64 - $344.58 $9,229 - $10,337	-30 Reduced 5.19%	548 $175,000
Q3 2017 Oct 24, 2017	BUY	$281.15 - $329.69 $162,504 - $190,560	578	578 $181,000

Others Institutions Holding BIIB

# of Institutions

1,038

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.

Account

Benjamin F. Edwards & Company, Inc. Biogen Inc. Transaction History